Loading stock data…
KYTX
$7.85+0.14 (+1.82%)
After Hours$7.58-0.27 (-3.44%)· Last close Jun 9
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kyverna Therapeutics, Inc. in the Healthcare sector is trading at $7.85. Wall Street consensus targets $30.40 (5 analysts), implying a +287.3% move over the next 12 months. The stock is currently 43% below its 52-week high of $13.67, remaining 1.8% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +287.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 34) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$7.85
Potential Downside
0%
Whystock Fair Value$7.85
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Mean target$30.40+287.3%
Range$25.00 – $33.00
Fundamentals
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment o...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-79.97%
Volume
Today's trading volume
717,760
Recent News
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026 outlook.
Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B
Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.
Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA
Kyverna Therapeutics (NASDAQ:KYTX) highlighted new clinical data for its CD19-directed autologous CAR T-cell therapy mivocabtagene autoleucel (miv-cel), formerly KYV-101, during an American Academy of Neurology (AAN) conference call focused on stiff person syndrome (SPS) and generalized myasthenia g
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry significant risk, but their late-stage pipelines and upcoming catalysts have convinced institutional investors to build substantial positions. All four trade with unanimous or near-unanimous Buy ratings, a ... Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why
KYTX's shares surge after positive phase II data showed its CAR T miv-cel delivered major mobility gains in stiff person syndrome.